


COPY RIGHT



ELSEVIER
SSRN

2023IJIEMR. Personal use of this material is permitted. Permission from IJIEMR must be obtained for all other uses, in any current or future media, including reprinting/republishing this material for advertising or promotional purposes, creating new collective works, for resale or redistribution to servers or lists, or reuse of any copyrighted component of this work in other works. No Reprint should be done to this paper, all copy right is authenticated to Paper Authors IJIEMR Transactions, online available on 25th May 2023.

Link : <https://ijiemr.org/downloads/Volume-12/Issue-05>

10.48047/IJIEMR/V12/ISSUE05/45

Title Techniques and Developments for Analysing Brain Neurochemistry

Pages: 461-468

Paper Authors

Dr J Nelson Samuel Jebastin, Dr. Khushal N. Pathade, M.Krishnaveni, Dr. Arshi Amin



USE THIS BARCODE TO ACCESS YOUR ONLINE PAPER

To Secure Your Paper As Per **UGC Guidelines** We Are Providing A Electronic Bar Code

Techniques and Developments for Analysing Brain Neurochemistry

¹**Dr J Nelson Samuel Jebastin,**

Assistant Professor in Bioinformatics, Department of Zoology, Annamalai University, Annamalainagar, Chidambaram, Cuddalore Dt., Tailnadu, India. 608 002.

nsjeba@yahoo.com

²**Dr. Khushal N. Pathade**

Assistant Professor and Head

P.G. Department of Botany

Dr. R. G. Bhojar Arts, Commerce and Science College, Seloo Dist. Wardha, Maharashtra

Email- pathade.khushal@gmail.com

³**M.Krishnaveni,**

Assistant Professor in Biochemistry, Nadar Saraswathi College of Arts & Science, Theni, Tamilnadu, India.

venibio87@gmail.com

⁴**Dr. Arshi Amin**

Associate Professor, Department of Chemistry, School of sciences

Noida International University, Greater Noida

arshi.amin@niu.edu.in

Abstract

In the brain, complex neural networks connect with each other over many orders of magnitude. Science's biggest problem is trying to figure out how this system affects how we see, remember, and act. Molecular biology, genetics, chemistry, physics, and engineering have all worked together to make brain study more advanced. Chemical communication between neurons, regulated by hundreds of neurotransmitters, neuromodulators, hormones, and other signalling molecules, is equally as vital but harder to understand than electrical excitation. Communication regulates motor control, learning, and behaviour. Researchers have used liquid chromatography, amperometry, and newly made light devices to study the chemical state of the brain. The writers look at functional fluorescence probes and device-based analysis methods that help them understand how brain activity is based on neurochemical processes. Here, the methods for making probes and devices are based on the way the brain works.

Keywords: Neurotransmitters; Neuromodulators; Amperometry; Probes;

Introduction

The nervous system is made up of neurons. So, basic neuroscience study needs to know how the brain works in the right place and at the right time. Around 80109 neurons and many trillion synaptic links make up the human brain. This huge and complicated network of neurons is what allows us to see, remember, and think. Understanding how brain networks produce unexpected events is a big scientific job [1].

Traditionally, brain study has centred on the structure and connections of neurons, the electrical activity of neurons, or the chemicals that send messages between neurons. The neuronal theory of modern neuroscience is based on Golgi's method of silver staining to show links between neurons. In the following decades, improvements in electrophysiology led to methods like whole cell patch clamp and aerometry that use electrodes to study the electrophysiology of neurons. Even though these are some of the most well-known methods to neuroscience, they can't be used to study large-scale brain activity. Fluorescence imaging can now look at the links between neural systems, as well as their electrical activity and chemical neurotransmission. Probes that can reach the spatial and temporal scales of each

viewpoint make this possible. We look at modern tools for brain activity, with a focus on fluorescence probes that measure chemical neurotransmission in the brain [2].

Chemical neurotransmitters

Neurons communicate by chemical signals across the synaptic gap (Fig. 1). Action potentials trigger intricate chemical processes in the presynaptic cell that transfer chemical signals into the synaptic cleft. Glutamate and GABA go via the synaptic gap to ligand-gated ion channels in the postsynaptic membrane. This binding generates rapid excitatory or inhibitory currents in the postsynaptic cell so presynaptic and postsynaptic neurons may communicate. This may affect action potential production. Neurotransmitters may alter neuron electrophysiology without producing an electrical current [3]. Neuromodulators slowly alter target neuron excitability by binding to G-protein coupled receptors (GPCRs). Electricity-induced neurotransmitter release is unpredictable and doesn't match neuronal activity. Complex neural networks' electrical messaging can be understood, but their chemical neurotransmission is harder. Thus, we need light devices to directly query chemical neurotransmission and interpret it. In response to this

requirement, new approaches have improved our understanding of how neurons and their circuits operate,

improving our understanding of the brain [4].




Fig.1 Chemicals communicate between presynaptic and postsynaptic neurons. Axons receive action potentials. Chemical synapses between presynaptic and postsynaptic neurons convert action potentials into chemical signals that may bridge the gap.

Imaging neuromodulator Problems with chemical discrimination

Neurons send out neurotransmitters, neuromodulators, neuropeptides, and hormones to talk to each other. Calcium and changes in electricity are still there. There are about 100 chemical molecules that send signals. The most common neurotransmitters in the brain are glutamate and GABA. These are the main ones that make you feel excited or calm down. DA, serotonin, and a number of

neuropeptides are all neuromodulators. These chemicals "tune" how excited the neurons they affect are and "modulate" how glutamate and GABA affect them. The fact that there are so many biological communication molecules and routes makes it harder to make selective tools. The ideal fluorescence probe would choose its target over neurotransmitters, precursors, and metabolites [5]. For excellent temporal resolution, high spatial resolution for recording, biofouling

resistance, and long-term bio stability, it would have ideal binding rates. To account for differences in amounts and release/reuptake patterns, the dissociation constant (K_d) of the probe must be adjusted for imaging in different parts of the brain. In spite of what you might think, high binding strengths don't always lead to better time clarity. But it's hard to meet all of these conditions. But improvements in protein engineering, precise genetic editing, making small glowing molecules in a lab, and making nanoparticles have made it possible to make new tools that can test neurochemistry in ways that are good for neuroscience study [6].

Fluorescent probes made from proteins

Fluorescent sensors made out of proteins link to neurotransmitters and give off light. By changing proteins that naturally link to the neurochemical substance, fluorescence sensors with correct information about space and time can be made. Fluorescent probes made from proteins have a dye that is chemically linked to the part that recognizes the substance. Analytes affect the recognition domain's shape. The fluorophore's photophysics change, indicating recognition. Protein-based monitors for neurotransmitters could use fluorophores that are made in a lab. After genetic translation, fluorescent proteins are

useful because they don't need any artificial parts [7].

FRET-protein sensors

Changing FRET is often the first step in making a sensor that can report on molecular changes. FRET can happen when the spectrum of absorption and emission of two fluorophores meet. FRET efficiency between a donor and a receiver fluorophore is very sensitive to distance. This makes it possible to accurately measure conformational changes on the nanometer scale that happen when a protein binds to a ligand. Most FRET-based probes change the FRET efficiency between the donor and recipient fluorophores by making biochemically driven changes to the spatial structure. The ratio metric output of FRET-based sensors gives numeric information about the characteristics of a process [8]. This needs delicate sensors. A ratio metric the design of a FRET-based sensor with two fluorophores needs a larger spectral spread than a single wavelength method. It is hard to multiplex FRET sensors, especially ones made of proteins that use fluorophores with similar fluorescence properties.

Glutamate-fluorescent protein

Fused enhanced cyan fluorescent protein (ECFP) and VENUS, a yellow fluorescent protein, to opposing ends of the glutamate-binding bacterium periplasmic protein to create FLIPE. FRET was initially employed in YbeJ protein sensors. [9] [Fig. 2(a)] YbeJ's glutamate binding and "hinge-bending" connect ECFP and VENUS and alter FRET. FLIPE-600n has a K_d of 600 nM and FLIPE-10 10 M. A pDisplay plasmid generates the sensor protein between two sequences and displays it on the cell's plasma membrane to locate FLIPE. FLIPE-600n exhibits a modest maximal ratio change (R_{max}) of

0.27 and a dynamic range of 100 nM to 1 M on PC12 cells, a model stem neuronal cell line [10]. FLIPE's modest fluorescence response makes studying neurotransmitter signalling difficult since probe signal and picture frame rate (temporal precision) are coupled incorrectly. Based on *E. coli* proteins that bind glutamine and histadine, YbeJ should bind and separate in 1 ms. Studying synapse release requires precise timing. The bound FLIPE architecture has not been fully dynamically tested for synapse neurotransmission. VENUS emission decreased in the initial tests longer than 30 minutes, which may restrict the length of investigations using such equipment [11].




Fig .2 Schematic of protein sensors that use FRET. (a) When glutamate is present, FLIPE on the surface of the cell "hinge-bends" in YbeJ (open circle) to bring ECFP and VENUS closer together. (b) The SNIFIT protein construct is "clicked" to DY-547 (star) and Cy5 (star attached to glutamate analog). Without glutamate, Cy5 binds to the iGluR5 receptor's S1S2 domain. Diamond glutamate beats out the other one and splits the colors, which changes how well FRET works. CNiFER cells with the right receptor bind external dopamine (the big

squares outside the cell) and release intracellular calcium (the small circles inside the cell) through a communication chain. TN-XXL binds to calcium that has been released and sends a FRET signal.

Neurotransmitter-fluorescent reporters

SNIFIT improved probe sensitivity, but FRET-based protein sensors still have low nanomolar analyte sensitivity, it's challenging to construct sensors for neurotransmitters like dopamine and norepinephrine (NE) that react via GPCRs, and there aren't many in vivo investigations. Cell-based neurotransmitter fluorescence engineered reporters (CNiFERS) attempt to solve these issues better than SNIFIT and FLIPE sensors. CNiFERS are clonal HEK293 cells modified to generate a natural GPCR that increases cell Ca^{2+} when attached to its endogenous ligand [Fig. 2(c)]. 2(c) using cyan and yellow fluorescent protein fluorophores [12] [Fig. 1].

Fluorescent reporters with a single wavelength

In contrast to FRET-based sensors, single wavelength sensors send a visual signal by changing the dye. This readout makes devices with small light excitation and emission bands that are easy to combine [13]. FRET devices are different from single frequency sensors because they use ratiometry to measure the

concentration of analytes. Single-wavelength sensors are not ratio metric, but they are more sensitive, which is hard to do in FRET systems with only small changes in the light signal.

Glutamate sensors

The FRET-based glutamate sensor FLIPE was improved by the glutamate optical sensor (EOS). AMPA receptor GluR2 changes create EOS. After E. coli expression, a cysteine residue at position 403 may add Oregon green to AMPA receptors. When streptavidin is combined with biotinylated cells, the altered protein attaches [14].

Glutamate-sensing fluorescence reporter based on intensity

EOS is not genetically encoded like the other systems in this section that employ proteins to perceive their environment. Genetically encoded sensors' facile targeting of particular cell populations, non-invasive sensor delivery, and recurrent imaging over months aren't used in the EOS approach.³ As a genetically encoded, single-wavelength alternative to EOS and superGluSnFR, iGluSnFR was developed. iGluSnFR, a circular green fluorescent

protein (cGFP) in *E. coli*, is broken up by the periplasmic binding protein GltI and glows faintly[15].

Probes for G-protein-coupled receptors (dLight, GRABDA, and Gach)

Given the merits of iGluSnFR, a comparable family of sensors has been constructed by adding circularly permuted GFP into the native G-protein coupled receptors for the target chemical. Without linking the binding protein to the pDisplay system, this technique couples analyte-induced structural changes to cGFP fluorescence. Natural receptors target neuromodulators like DA and Ach[16]. Two dopamine devices dLight and GRABDA were designed this way. Dopamine receptors in cGFP generated both probes. Different dLight probes insert the cGFP module sequence into the third intracellular loop (IL3) of human dopamine D1, D2, and D4 receptors. cGFP makes dLight1.1 and 1.2. Both sensors have 230 9% and 340 20% f/fmax. These mutants exhibit 330 30 and 770 10 nM dopamine affinities and excellent binding rates. GRABDA is produced by inserting cEGFP into the human dopamine D2 receptor's IL3. GRABDA1m and GRABDA1h exist. Both exhibit 90% Fmax/F0 reactions, although their values are 130 and 10 nM[17].

Man-made tools

In contrast to methods that use proteins, synthetic probes use non-natural structures to bind to and send signals to neurotransmitters. Synthetic methods for detecting neurotransmitters use parts from fields other than biology to identify chemicals and send signals. The time precision, sensitivity, selectivity, and biocompatibility of these instruments are all achieved in different ways. We use both molecular-scale and device-scale ways to sense manufactured neurotransmitters. Both systems use sensors with similar chemical recognition or signal-transducing molecules[18]. They work in different ways. Approaches that work at the device scale put molecular identification and signal-transduction moles on chips or probes. However, molecular-scale approaches structure their signal transmission and identification components into molecular units.

Synthesis of molecules

Device-based probes aren't "free" like molecular probes. Due to its more sensors and smaller brain target areas, molecular probes may have superior spatial clarity than device-based probes [19].

Nanogold particles

Gold nanoparticles (Au NP) are utilized as imaging agents because they may modify their absorption and emission characteristics and surface compounds. Colorimetric sensors employ Au NPs because their color varies with plasmon resonance frequency. Colorimetric sensors respond without tools or telescopes. Thus, gold nanoparticles assist lab-bench sensors. Most Au NP-based neurotransmitter sensors monitor blood or serum neurotransmitter [20].

One-walled carbon nanotubes

SWNT sensors employ a signalling chemical that fluoresces in the near infrared (NIR) when excitons recombine along the one-dimensional nanoparticle, unlike gold nanoparticle-based sensors. The NIR window enhances tissue sensing in vivo and in vitro. Haemoglobin and water don't absorb light in NIR I (650–950 nm), making deep tissue imaging difficult. The NIR II transparency window (1000–1350 nm) enables light penetrate tissues deeper than NIR I. NIR fluorophores for tissue imaging have reduced diffusion and absorption [21]. Thus, single-wall carbon nanotubes' NIR band gap has been employed to monitor tissue biological events. SWNT-based sensors retain light after 10 hours of stimulation. This allows long-term sampling to examine changes.

SWNTs for chemical identification need a component that detects neurotransmitters and alters their fluorescence when they link to their targets. Biomimetic plastic strands power SWNTs. Polymer-functionalized SWNTs generate a nanotube corona phase by attracting polymeric threads to the nanoparticle. SWNT surface-adsorbed polymers bind neurotransmitters and alter nanotube coronas. SWNT fluorescence alters [22].

FM dyes, blazing pseudo neurotransmitters

FFNs and FM dyes (named after their originator, Fei Mao) can study neurotransmitter release patterns. Neurotransmitters are released by cell synaptic action potentials. These neurotransmitters activate post-synaptic receptors [23]. This chemicalizes the action potential. Neurons release nanometer-sized vesicles into the synaptic cleft when action potentials fuse the membrane. Vesicles contain chemicals. Transporters swiftly remove signalling molecules from the synaptic gap to prepare for action potentials and neurotransmitter releases. Vesicular transporter proteins transfer neurotransmitters into vesicles for metabolic processing and release. FFNs witness neurochemical release from neurotransmitter exocytosis. Neurons take

up FFNs and place them in vesicles alongside their endogenous counterparts. FFNs image neurotransmitter release at a single release point (synaptic) and provide synaptic release chance, a key metric of synaptic plasticity [24].

Device probes

Device-based approaches below don't display location or readouts. Device-based approaches may be faster than visual ones. Two neurochemistry-related inventions preceded luminous chemical instruments [25]. Micro dialysis was one of the earliest approaches to detect and quantify brain fluid analytes. Electrochemistry is often used to study brain redox-active substances. In brain research, we discuss both methodologies and compare their temporal and spatial accuracy, uniqueness, and mixing. FET devices are examined after reviewing neurological device-based approaches [26].

Micro dialysis

Micro dialysis is one of the earliest brain neurochemistry studies. It examines interstitial brain tissue samples using liquid chromatography, capillary electrophoresis, mass spectrometry, and electrochemistry. Micro dialysis involves inserting a dialysis probe with a tubular semipermeable membrane into a sleeping

or awake animal's brain. A perfusate with the same ionic balance as external fluid flushes the probe after insertion. A "blank perfusate" has the same osmolality as cerebrospinal fluid but without the researcher's small molecule analytes. Dialysis membrane ionic concentration gradients don't disrupt brain tissue surrounding the probe if they're balanced. Neurotransmitters, hormones, and metabolites may readily enter the perfusate from the extracellular region along their concentration gradient. The exit tube collects steady perfusate for scientific study. Micro dialysis finds hormones, neuropeptides, and neurotransmitters best. Micro dialysis can evaluate several analytes without considering ligand binding. It can evaluate numerous samples simultaneously. Micro dialysis can monitor several analytes in multiple locations. Electrochemical approaches can measure neurotransmitters, neuropeptides, hormones, and signalling molecules such as somatostatin, prolactin, and cyclic AMP [27].

Voltammetry and amperometry are common electrical techniques for studying dopamine, norepinephrine, serotonin, and their derivatives in the brain. These methods can detect analyte concentration changes in milliseconds, quicker than

micro dialysis. These methods are based on microelectrode voltage chemical analysis. Redox chemistry generates a current that may be monitored to determine analyte concentration. A voltammogram, or current voltage plot, depicts the chemical name and amount of a sample as the voltage changes over time inside a potential window. The working electrode's rapid potential sweep allows high-resolution brain chemical transient detection. FSCV is used. FSCV has taught us about catecholamines, especially dopaminergic systems. Both the dorsal striatum and nucleus accumbens have dopamine terminals[28]. FSCV is utilized to research dopamine neuromodulation because dopaminergic terminals are equally distributed, have many connections, and are readily detected. FSCV employs 10-second cyclic pulses. It can precisely recreate dopamine chemistry by recording brief spikes and decreases. FSCV sensors are too large to assess the neocortex's few dopamine receptors. FSCV tests electroactive serotonin. Like dopamine, serotonin communicates with brain-wide GPCR receptors. Neuroscience experts are interested in it because it affects depression causes and treatments. FSCV is only present in powerfully and densely innervated brain regions such the substantia nigra pars reticulata,

hypothalamus, and thalamus. FETs change the electric field surrounding them. FETs detect neurotransmitter-induced electric field changes in numerous devices. FETs detect low analyte concentrations. FETs can communicate with other medical equipment and micro fabricate sensors fast and affordably [29].

Li and colleagues created a dopamine FET sensor. DNA aptamers replaced protein receptors. Aptamers, smaller than protein receptors, may bring connected dopamine molecules closer to the FET surface to create larger electric field changes and signals. Aptamers refold and withstand heat better than proteins. Li et al. employ a multiple-parallel-connected silicon nanowire FET with interdigitated source and drain wires and directly attach the neurotransmitter-binding aptamer to the FET's surface instead of Kim's carbon nanotube design. The completed FET dopamine sensor has a comparable broad linear working range of 10 pM–100 nM, a 120 pM dissociation constant K_d for dopamine, and 50-fold and 10-fold greater sensitivity for dopamine than epinephrine and norepinephrine, respectively. These parameters allow real-time hypoxic PC12 cell dopamine release tracking [30].


Conclusion

Chemical communication by neurons impacts their excitability. Neurochemical status influences several brain processes and issues. Patch clamp electrophysiology cannot reveal how networks of neurons in various brain regions work together to generate memory, learning, and behaviour. Scalable technologies that evaluate neurochemistry at brain-appropriate spatial and temporal scales are needed to comprehend brain neurochemistry. Genetically engineered fluorescent protein probes can precisely target neuron groupings. Proteins make most bioluminescent indicators. However, many artificial fluorescent probes operate in lab cell cultures and other reduced preparations, but few work in actual beings. Manufactured tools must function and be safe. Synthetic approaches must have excellent signal-to-noise ratios, binding speeds, photo stability, and minimal cytotoxicity for video-rate fluorescence imaging. FSCV and micro dialysis have contributed to neurochemistry despite its spatial clarity and inability to differentiate cells. Synthetic chemists, nanotechnologists, and protein builders may lead brain function research using innovative neurochemistry methodologies.

Reference

1. J. S. Marvin et al., *Nat. Methods* 10, 162 (2013).
2. D. Spiering, J. J. Bravo-Cordero, Y. Moshfegh, V. Miskolci, and L. Hodgson, *Methods Cell Biol.* 114, 593 (2013).
3. D. M. Grant et al., *Biophys. J.* 95, L69 (2008).
4. S. Okumoto, L. L. Looger, K. D. Micheva, R. J. Reimer, S. J. Smith, and W. B. Frommer, *Proc. Natl. Acad. Sci. U.S.A.* 102, 8740 (2005).
5. D. M. Miller III, J. S. Olson, J. W. Pflugrath, and F. A. Quioco, *J. Biol. Chem.* 258, 15665 (1983), available at <http://www.jbc.org/content/258/22/13665.short>.
6. Masharina, L. Reymond, D. Maurel, K. Umezawa, and K. Johnsson, *J. Am. Chem. Soc.* 134, 19026 (2012). 11A. Schena and K. Johnsson, *Angew. Chem. Int. Ed.* 53, 1302 (2014).
7. G. Yang et al., *Nat. Methods* 12, 137 (2015).
8. E. Lacin, A. Muller, M. Fernando, D. Kleinfeld, and P. A. Slesinger, *J. Vis. Exp.* 111, 53290 (2016).
9. Q.-T. Nguyen, L. F. Schroeder, M. Mank, A. Muller, P. Taylor, O.

- Griesbeck, and D. Kleinfeld, *Nat. Neurosci.* 13, 127 (2010).
10. Muller, V. Joseph, P. A. Slesinger, and D. Kleinfeld, *Nat. Methods* 11, 1245 (2014).
11. N. Nakatsuka and A. M. Andrews, *ACS Chem. Neurosci.* 8, 218 (2017).
12. S. Namiki, H. Sakamoto, S. Inuma, M. Iino, and K. Hirose, *Eur. J. Neurosci.* 25, 2249 (2007).
13. Y. Okubo, H. Sekiya, S. Namiki, H. Sakamoto, S. Inuma, M. Yamasaki, M. Watanabe, K. Hirose, and M. Iino, *Proc. Natl. Acad. Sci. U.S.A.* 107, 6526 (2010).
14. J. S. Marvin et al., *Nat. Methods* 15, 936 (2018).
15. S. K. Nune, P. Gunda, P. K. Thallapally, Y.-Y. Lin, M. L. Forrest, and C. J. Berkland, *Expert Opin. Drug Deliv.* 6, 1175 (2009).
16. Y. Zheng, Y. Wang, and X. Yang, *Sens. Actuators B Chem.* 156, 95 (2011).
17. E. M. McConnell, M. R. Holahan, and M. C. DeRosa, *Nucleic Acid Ther.* 24, 388 (2014). 23J. L. Chávez, J. A. Hagen, and N. Kelley-Loughnane, *Sensors* 17, 681 (2017).
18. N. Harata, T. A. Ryan, S. J. Smith, J. Buchanan, and R. W. Tsien, *Proc. Natl. Acad. Sci. U.S.A.* 98, 12748 (2001).
19. V. I. Chefer, A. C. Thompson, A. Zapata, and T. S. Shippenberg, *Curr. Protoc. Neurosci.* 47, 7.1.1 (2009).
20. H. Benveniste, *J. Neurochem.* 52, 1667 (1989).
21. N. Plock and C. Kloft, *Eur. J. Pharm. Sci.* 25, 1 (2005).
22. T. Zetterström, T. Sharp, A. K. Collin, and U. Ungerstedt, *Eur. J. Pharmacol.* 148, 327 (1988).
23. J. Bourdelais and P. W. Kalivas, *J. Neurochem.* 58, 2311 (1992).
24. L. J. Petersen, J. K. Kristensen, and J. Bülow, *J. Invest. Dermatol.* 99, 357 (1992).
25. K. M. Kendrick, E. B. Keverne, C. Chapman, and B. A. Baldwin, *Brain Res.* 439, 1 (1988).
26. H. Lahtinen, J. Brankack, E. Koivisto, and P. J. Riekkinen, *Brain Res. Bull.* 29, 837 (1992).
27. B. Linderöth, B. Gazelius, J. Franck, and E. Brodin, *Neurosurgery* 31, 289 (1992).
28. K. T. Ngo, E. L. Varner, A. C. Michael, and S. G. Weber, *ACS Chem. Neurosci.* 8, 329 (2017).



29. H. Yang, M. M. Sampson, D. Senturk, and A. M. Andrews, ACS Chem. Neurosci. 6, 1487 (2015).
30. K. T. Kawagoe, J. B. Zimmerman, and R. M. Wightman, J. Neurosci. Methods 48, 225 (1993)